Thanks. That confirms my understanding from the first PR. If I'm not mistaken, today's report seems to be basically a quantification of the effect for one of the dosages.
"What they are probably looking for is something that can be given at the leading edge of an infection wave to stop the early outbreak." I think of that as a vaccine's function ("prophylactic acting virucide") in the sense that it would have to be broadly dispensed without a diagnosis of disease.
I guess we won't learn anything about the treatment potential until the lung cell results are reported.